147.94+0.13+0.09%
After-market 06:58:46 PM EDT 6/4/2024BTT
Plus500. 81% of retail CFD accounts lose money
147.81-0.01-0.01%
Official Close 03:59:59 PM EDT 6/4/2024BTT
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Monday 06/03/2024 the closing price of the Johnson & Johnson share was $147.81 on BTT.Compared to the opening price on Monday 06/03/2024 on BTT of $146.87, this is a gain of 0.64%.Johnson & Johnson's market capitalization is $355.50 B by 2.41 B shares outstanding.
Is Johnson & Johnson stock a Buy, Sell or Hold?
Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 46 buy ratings, 32 hold ratings, and 1 sell ratings.What was the 52-week low for Johnson & Johnson stock?
The low in the last 52 weeks of Johnson & Johnson stock was 143.15. According to the current price, Johnson & Johnson is 103.35% away from the 52-week low.What was the 52-week high for Johnson & Johnson stock?
The high in the last 52 weeks of Johnson & Johnson stock was 175.96. According to the current price, Johnson & Johnson is 84.08% away from the 52-week high.What are analysts forecasts for Johnson & Johnson stock?
The 79 analysts offering price forecasts for Johnson & Johnson have a median target of 184.73, with a high estimate of 215.00 and a low estimate of 40.00. The median estimate represents a 80.08 difference from the last price of 147.94.Johnson & Johnson Stock Snapshot
147.72
Bid
51.00
Bid Size
147.86
Ask
6/4/2024
Date
6:58 PM
Time
304,949.00
Volume
147.81
Prev. Close
147.62
Open
355.50 B
Market Cap
2.41 B
Number of Shares
146.19
Day Low
148.31
Day High
147.94
143.15
52 Week Low
175.96
52 Week High
147.94
4.81
Dividend
3.25
Dividend Yield
15.80
P/E Ratio
99.84
Free Float in %
10.64
EPS 2024
31.52
Book Value per Share
11.44
Cash Flow per Share
Johnson & Johnson NewsMore News
InvestorPlace
The 3 Most Undervalued Dow Stocks to Buy in June 2024
TipRanks
InvestorPlace
3 Dividend Aristocrats to Scoop Up During Market Pullbacks in June
Historical Prices for Johnson & Johnson
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Johnson & Johnson Analyst Data
Total Analysts: 79
Buy Ratings: 46 Neutral Ratings: 32 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 40.00 Median: 184.73 Highest: 215.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Johnson & Johnson Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 06/04/24 | RBC Capital Markets | Maintained Buy | $175 | gut | ||
| 05/22/24 | RBC Capital Markets | Maintained Buy | $175 | gut | ||
| 05/16/24 | RBC Capital Markets | Maintained Buy | $175 | gut | ||
| 05/06/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 04/18/24 | HSBC | Upgraded to Buy | $170 | gut | ||
| 04/17/24 | RBC Capital Markets | Maintained Buy | $175 | gut | ||
| 04/17/24 | Bank of America Merrill Lynch | Maintained Hold | $170 | neutral | ||
| 04/15/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 03/13/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 02/28/24 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 02/20/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 02/06/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/24/24 | Morgan Stanley | Maintained Hold | $169 | neutral | ||
| 01/24/24 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 01/23/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/09/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/03/24 | Raymond James Financial, Inc. | Maintained Buy | $175 | gut | ||
| 12/13/23 | Wells Fargo & Co | Downgraded to Hold | $163 | neutral | ||
| 12/06/23 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 12/01/23 | RBC Capital Markets | Maintained Buy | $178 | gut | ||
| 12/01/23 | UBS | Upgraded to Buy | $180 | gut | ||
| 11/20/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 11/17/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/23/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/18/23 | Morgan Stanley | Maintained Hold | $171 | neutral | ||
| 10/18/23 | Raymond James Financial, Inc. | Maintained Buy | $172 | gut | ||
| 10/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/12/23 | Barclays Capital | Maintained Hold | $162 | neutral | ||
| 10/11/23 | Morgan Stanley | Maintained Hold | $174 | neutral | ||
| 10/09/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/05/23 | RBC Capital Markets | Maintained Buy | $178 | gut | ||
| 10/02/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/08/23 | Barclays Capital | Maintained Hold | $158 | neutral | ||
| 09/06/23 | HSBC | Maintained Sell | $175 | schlecht | ||
| 09/05/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/05/23 | Raymond James Financial, Inc. | Maintained Buy | $179 | gut | ||
| 08/31/23 | Wells Fargo & Co | Maintained Buy | $186 | gut | ||
| 08/31/23 | Morgan Stanley | Maintained Hold | $172 | neutral | ||
| 08/30/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 08/22/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 08/04/23 | Atlantic Equities | Maintained Hold | $170 | neutral | ||
| 07/31/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 07/25/23 | Barclays Capital | Maintained Hold | $175 | neutral | ||
| 07/24/23 | Raymond James Financial, Inc. | Maintained Buy | $184 | gut | ||
| 07/21/23 | J.P. Morgan | Maintained Hold | $180 | neutral | ||
| 07/21/23 | Morgan Stanley | Maintained Hold | $187 | neutral | ||
| 07/21/23 | Credit Suisse | Maintained Hold | $175 | neutral | ||
| 07/13/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 07/11/23 | Morgan Stanley | Maintained Hold | $187 | neutral |
Johnson & Johnson Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 88,349 | 90,806 | 93,936 | 97,064 | 102,732 |
| Dividend | 4.81 | 5.02 | 5.24 | 5.77 | 6.38 |
| Dividend Yield (in %) | 3.26 % | 3.40 % | 3.55 % | 3.91 % | 4.32 % |
| EPS | 10.65 | 10.95 | 11.43 | 11.76 | 12.47 |
| P/E Ratio | 13.88 | 13.49 | 12.93 | 12.57 | 11.85 |
| EBIT | 29,008 | 29,898 | 31,091 | 31,700 | 33,834 |
| EBITDA | 33,208 | 34,143 | 35,746 | 38,901 | 38,233 |
| Net Profit | 25,877 | 26,532 | 27,561 | 27,812 | 29,402 |
| Net Profit Adjusted | 25,877 | 26,532 | 27,561 | 27,812 | 29,402 |
| Pre-Tax Profit | 30,931 | 31,667 | 32,914 | 33,292 | 35,030 |
| Net Profit (Adjusted) | 25,125 | 25,964 | 26,617 | 26,705 | 27,843 |
| EPS (Non-GAAP) ex. SOE | 10.73 | 11.13 | 11.51 | 11.22 | - |
| EPS (GAAP) | 8.61 | 9.13 | 10.32 | 9.75 | 10.16 |
| Gross Income | 65,986 | 68,047 | 70,439 | 74,466 | 78,478 |
| Cash Flow from Investing | -7,245 | -5,617 | -5,654 | -5,808 | -6,547 |
| Cash Flow from Operations | 27,477 | 27,080 | 27,363 | 29,186 | 31,985 |
| Cash Flow from Financing | -9,903 | -15,513 | -15,868 | -20,160 | -20,846 |
| Cash Flow per Share | 11.44 | 11.79 | 13.27 | - | - |
| Free Cash Flow | 23,337 | 23,121 | 23,896 | 25,377 | 29,358 |
| Free Cash Flow per Share | 11.01 | 8.78 | 8.80 | - | - |
| Book Value per Share | 31.52 | 34.82 | 38.57 | 34.68 | 36.40 |
| Net Debt | -5,725 | -17,383 | -28,983 | -29,062 | - |
| Research & Development Exp. | 14,976 | 15,336 | 15,758 | 16,287 | 16,913 |
| Capital Expenditure | 4,144 | 4,169 | 4,235 | 4,359 | 4,047 |
| Selling, General & Admin. Exp. | 21,979 | 22,509 | 23,174 | 24,048 | 25,060 |
| Shareholder’s Equity | 77,504 | 84,930 | 92,866 | 87,652 | 105,119 |
| Total Assets | 179,190 | 185,808 | 192,290 | 188,220 | 206,672 |
| Previous Quarter ending 03/31/24 | Current Quarter ending 06/30/24 | Next Quarter ending 09/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 16 | 16 | 16 | 20 | 20 |
| Average Estimate | 2.656 USD | 2.714 USD | 2.689 USD | 10.647 USD | 10.953 USD |
| Year Ago | 2.680 USD | 2.800 USD | 2.660 USD | 9.920 USD | 10.647 USD |
| Publish Date | 4/16/2024 | 7/16/2024 | 10/15/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 14 | 14 | 14 | 19 | 19 |
| Average Estimate | 21,401 USD | 22,303 USD | 22,215 USD | 88,349 USD | 90,806 USD |
| Year Ago | 24,746 USD | 25,530 USD | 21,351 USD | 85,159 USD | 88,349 USD |
| Publish Date | 4/16/2024 | 7/16/2024 | 10/15/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales | 76,481 | 81,534 | 82,113 | 82,572 | 93,758 | 95,015 | 85,152 |
| Change of sales in % | 6.32 | 6.61 | 0.71 | 0.56 | 13.55 | 1.34 | -10.38 |
| Gross profit on sales | 51,374 | 54,348 | 54,978 | 54,574 | 63,884 | 64,297 | 58,722 |
| Gross profit on sales change in % | 2.14 | 5.79 | 1.16 | -0.73 | 17.06 | 0.65 | -8.67 |
| Operating income | 19,565 | 21,253 | 21,550 | 20,468 | 24,481 | 24,780 | 22,162 |
| Operating income change in % | -8.36 | 8.63 | 1.40 | -5.02 | 19.61 | 1.22 | -10.56 |
| Income before tax | 17,673 | 17,999 | 17,328 | 16,497 | 22,776 | 21,725 | 15,062 |
| Income before tax change in % | -10.76 | 1.84 | -3.73 | -4.80 | 38.06 | -4.61 | -30.67 |
| Income after tax | 1,300 | 15,297 | 15,119 | 14,714 | 20,878 | 17,941 | 14,169 |
| Income after tax change in % | -92.14 | 1,076.69 | -1.16 | -2.68 | 41.89 | -14.07 | -21.02 |
Balance Sheet
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 97,143 | 93,202 | 98,257 | 111,616 | 107,995 | 110,574 | 98,784 |
| Total liabilities change in % | 24.83 | 23.28 | 23.66 | 26.26 | 23.88 | 20.96 | 21.81 |
| Equity | 60,160 | 59,752 | 59,471 | 63,278 | 74,023 | 76,804 | 68,774 |
| Equity change in % | -14.57 | -0.68 | -0.47 | 6.40 | 16.98 | 3.76 | -10.46 |
| Balance sheet total | 157,303 | 152,954 | 157,728 | 174,894 | 182,018 | 187,378 | 167,558 |
| Balance sheet total change in % | 11.40 | -2.76 | 3.12 | 10.88 | 4.07 | 2.94 | -10.58 |
Key Data
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 27.86 | 29.88 | 30.59 | 30.92 | 35.06 | 35.67 | 33.26 |
| P/E ratio (year end quote, basic EPS) | 297.28 | 22.69 | 25.88 | 28.57 | 21.91 | 26.23 | 28.32 |
| P/E ratio (ear end quote, diluted EPS) | 297.28 | 22.69 | 25.88 | 28.57 | 21.91 | 26.23 | 28.32 |
| P/E ratio (year end quote) | 297.28 | 22.69 | 25.88 | 28.57 | 21.91 | 26.23 | 28.32 |
| Dividend yield in % | 2.38 | 2.78 | 2.57 | 2.53 | 2.45 | 2.52 | 3.00 |
| Equity ratio in % | 38.24 | 39.07 | 37.70 | 36.18 | 40.67 | 40.99 | 41.04 |
| Debt ratio in % | 61.76 | 60.93 | 62.30 | 63.82 | 59.33 | 59.01 | 58.96 |
Johnson & Johnson Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| REED JOHN C | 04/30/2024 | 10,984.00 | 11,577.00 | 144.59 | Sell | No |
| REED JOHN C | 04/30/2024 | 22,255.00 | 22,561.00 | n/a | Buy | No |
| Broadhurst Vanessa | 03/12/2024 | 8,891.00 | 15,043.00 | 162.16 | Sell | No |
| Wolk Joseph J | 02/12/2024 | 773.00 | 68,890.00 | 157.85 | Sell | No |
| Taubert Jennifer L | 02/12/2024 | 666.00 | 154,851.00 | 157.85 | Sell | No |
| Decker Robert J | 02/12/2024 | 86.00 | 18,973.00 | 157.85 | Sell | No |
| Wengel Kathryn E | 02/12/2024 | 333.00 | 82,265.87 | 157.85 | Sell | No |
| Forminard Elizabeth | 02/12/2024 | 236.00 | 8,340.00 | 157.85 | Sell | No |
| Decker Robert J | 02/12/2024 | 313.00 | 19,059.00 | n/a | Buy | No |
| Taubert Jennifer L | 02/12/2024 | 1,302.00 | 155,517.00 | n/a | Buy | No |
| Wolk Joseph J | 02/12/2024 | 1,780.00 | 69,663.00 | n/a | Buy | No |
| Wengel Kathryn E | 02/12/2024 | 651.00 | 82,598.87 | n/a | Buy | No |
| Forminard Elizabeth | 02/12/2024 | 651.00 | 8,576.00 | n/a | Buy | No |
| Hait William | 02/11/2024 | 4,076.00 | 38,240.00 | 157.40 | Sell | No |
| Fasolo Peter | 02/11/2024 | 7,019.00 | 111,625.00 | 157.40 | Sell | No |
| Duato Joaquin | 02/11/2024 | 15,900.00 | 361,339.00 | 157.40 | Sell | No |
| Swanson James D. | 02/11/2024 | 1,695.00 | 14,318.00 | 157.40 | Sell | No |
| Wolk Joseph J | 02/11/2024 | 10,816.00 | 67,883.00 | 157.40 | Sell | No |
| Taubert Jennifer L | 02/11/2024 | 13,403.00 | 154,215.00 | 157.40 | Sell | No |
| Wengel Kathryn E | 02/11/2024 | 7,066.00 | 81,947.87 | 157.40 | Sell | No |
| Schmid Timothy | 02/11/2024 | 2,887.00 | 12,791.00 | 157.40 | Sell | No |
| Broadhurst Vanessa | 02/11/2024 | 2,136.00 | 23,735.00 | 157.40 | Sell | No |
| Decker Robert J | 02/11/2024 | 523.00 | 18,746.00 | 157.40 | Sell | No |
| Forminard Elizabeth | 02/11/2024 | 1,034.00 | 7,925.00 | 157.40 | Sell | No |
| Hait William | 02/11/2024 | 1,285.00 | 42,316.00 | n/a | Buy | No |
Johnson & Johnson Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Johnson & Johnson | 4.70 | 3.00 | USD |
| 2022 | Johnson & Johnson | 4.45 | 2.52 | USD |
| 2021 | Johnson & Johnson | 4.19 | 2.45 | USD |
| 2020 | Johnson & Johnson | 3.98 | 2.53 | USD |
| 2019 | Johnson & Johnson | 3.75 | 2.57 | USD |
| 2018 | Johnson & Johnson | 3.54 | 2.78 | USD |
| 2017 | Johnson & Johnson | 3.32 | 2.38 | USD |
| 2016 | Johnson & Johnson | 3.15 | 2.73 | USD |
| 2015 | Johnson & Johnson | 2.95 | 2.87 | USD |
| 2014 | Johnson & Johnson | 2.76 | 2.63 | USD |
| 2013 | Johnson & Johnson | 2.59 | 2.80 | USD |
| 2012 | Johnson & Johnson | 2.40 | 3.45 | USD |
| 2011 | Johnson & Johnson | 2.25 | 3.43 | USD |
| 2010 | Johnson & Johnson | 2.11 | 3.41 | USD |
| 2009 | Johnson & Johnson | 1.93 | 3.00 | USD |
| 2008 | Johnson & Johnson | 1.79 | 3.06 | USD |
| 2007 | Johnson & Johnson | 1.62 | 2.43 | USD |
| 2006 | Johnson & Johnson | 1.46 | 2.21 | USD |
| 2005 | Johnson & Johnson | 1.27 | 2.11 | USD |
| 2004 | Johnson & Johnson | 1.09 | 1.72 | USD |
| 2003 | Johnson & Johnson | 0.92 | 1.82 | USD |
| 2002 | Johnson & Johnson | 0.79 | 1.47 | USD |
| 2001 | Johnson & Johnson | 0.70 | 1.17 | USD |
| 2000 | Johnson & Johnson | 0.62 | 1.18 | USD |
| 1999 | Johnson & Johnson | 0.55 | 1.18 | USD |
*Yield of the Respective Date
Johnson & Johnson Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.714 USD | Q2 2024 Earnings Release | 07/16/2024 |
| Earnings Report | 2.689 USD | Q3 2024 Earnings Release | 10/15/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 01/28/2025 |
| Earnings Report | - | Q1 2025 Earnings Release | 04/22/2025 |
Johnson & Johnson Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 04/25/2024 |
| Earnings Report | 2.710 USD | Q1 2024 Earnings Release | 04/16/2024 |
| Press Conference | - | - | 04/16/2024 |
| Press Conference | - | - | 01/23/2024 |
| Press Conference | - | - | 10/17/2023 |
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Johnson & Johnson Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.84 |
| The Vanguard Group, Inc. | 9.52 |
| Vanguard Group, Inc. (Subfiler) | 9.08 |
| State Street Corp. | 5.54 |
| SSgA Funds Management, Inc. | 5.52 |
| Vanguard Total Stock Market ETF | 3.15 |
| BlackRock Fund Advisors | 2.93 |
| Vanguard 500 Index Fund | 2.54 |
| Geode Capital Management LLC | 2.21 |
| BlackRock Institutional Trust Co. NA | 2.20 |
| State Farm Investment Management Corp. | 1.31 |
| Fidelity 500 Index Fund | 1.21 |
| Norges Bank (13F) | 1.08 |
| Government Pension Fund - Global (The) | 1.05 |
| Wellington Management Co. LLP | 0.99 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Johnson & Johnson Management
| Name | Job |
|---|---|
| Joaquin Duato | Chairman & Chief Executive Officer |
| Robert J. Decker | Chief Accounting Officer & Controller |
| Ronald A. Kapusta | Chief Accounting Officer & Controller |
| Frederic H. Moll | Chief Development Officer |
| William N. Hait | Chief External Innovation & Executive VP-Medical |
| Joseph J. Wolk | Chief Financial Officer & Executive Vice President |
| Paul Ruh | Chief Financial Officer-Consumer Health |
| Peter M. Fasolo | Chief Human Resources Officer & Executive VP |
| James D. Swanson | Chief Information Officer & Executive VP |
| Kathryn E. Wengel | Chief Technical Operations & Risk Officer |
| Jonathan Sheh | Director-Workplace Experience |
| Jennifer L. Taubert | EVP & Worldwide Chairman-Innovative Medicine |
| Timothy Schmid | Executive Vice President & Chairman-Worldwide |
| Elizabeth Forminard | Executive Vice President & General Counsel |
| John C. Reed | Executive Vice President-Innovative Medicine |
| Michael Bzdak | Global Dir-Employee Engagement-Global Cmnty Impact |
| George Davy | Global HR Director |
| Caroline Tillett | Global Head-Consumer Health |
| Neil Ackerman | Head-Innovation, Global Supply & Transformation |
| Nadja Y. West | Independent Director |
| Paula A. Johnson | Independent Director |
| Mary C. Beckerle | Independent Director |
| Mark Alan Weinberger | Independent Director |
| Mark B. McClellan | Independent Director |
| Hubert Joly | Independent Director |
| Jennifer A. Doudna | Independent Director |
| Anne M. Mulcahy | Independent Director |
| Eugene A. Woods | Independent Director |
| D. Scott Davis | Independent Director |
| Darius Adamczyk | Independent Director |
| Marillyn A. Hewson | Lead Independent Director |
| Thomas J. Spellman | Secretary |
| Marc Larkins | Secretary & Vice President-Governance |
| Meredith Stevens | Vice President |
| Jessica Moore | Vice President-Investor Relations |
| William E. Cohn | Vice President-Medical Devices |
| Lisa Paley | Vice President-US Sales |
